Suppression of prostate cancer cell rolling and adhesion to endothelium by 1α,25-dihydroxyvitamin D3.
about
In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right PlatformCirculating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flowCommonalities in the Association between PPARG and Vitamin D Related with Obesity and CarcinogenesisEffect of homotypic and heterotypic interaction in 3D on the E-selectin mediated adhesive properties of breast cancer cell linesHuman fucosyltransferase 6 enables prostate cancer metastasis to boneThe impact of vitamin D pathway genetic variation and circulating 25-hydroxyvitamin D on cancer outcome: systematic review and meta-analysisThe anti-cancer and anti-inflammatory actions of 1,25(OH)₂D₃Vitamin D safety and requirements.Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control studyPotent 19-norvitamin D analogs for prostate and liver cancer therapyDecreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor.Modeling prostate cancer in mice: limitations and opportunities1 alpha, 25-dihydroxylvitamin D3 promotes Bacillus Calmette-Guérin immunotherapy of bladder cancer.Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood.Vitamin D in cancer chemoprevention.Vitamin D receptor agonist EB1089 is a potent regulator of prostatic "intracrine" metabolism.E-selectin ligand-1 controls circulating prostate cancer cell rolling/adhesion and metastasis.PDLIM2 expression is driven by vitamin D and is involved in the pro-adhesion, and anti-migration and -invasion activity of vitamin D.Exploring vitamin D metabolism and function in cancer.
P2860
Q26767210-FEB47E79-CB4F-4A0A-BDD8-E49F7F327CCEQ27334142-EFC980BD-04EE-4BA7-9092-6D228F4DFD85Q28070220-2B4210B5-6C4F-4060-B658-99D31B4A9465Q30529166-C1874E3F-082A-421F-AC8F-86DB589A28ACQ30559315-48A1611E-570B-4DC7-8B38-FA4D395264EEQ33577607-1F33D88E-4B66-4ED2-A0D5-B4EBA4081727Q35188826-438710A9-2DB1-4366-A6FB-F1960E69DFFFQ35850965-99A31C8E-175A-4C1A-942A-A310BA6F2D45Q35925515-EAACC95B-1C82-4E5D-8825-2CEE159F06E7Q36682230-77D8DF14-9C50-433B-AA59-BB60C5519A97Q36817627-2D31D67C-D051-4DC5-A1DC-C2D64CD68C34Q37053034-D17CF784-C5A2-4EB4-B054-00E04E18145BQ37589142-FFFDED8B-C9A1-4B02-B9D9-685EE079F8ABQ38387142-94F2FF46-CC7F-4AF2-A8B4-EDB1B116ED6EQ38412880-F5EB896D-DDF0-4CE7-B366-77D1E4323C9DQ39062220-8D7D5F1C-2E67-40F8-9F6A-7B0E891D8DB5Q42123362-67A0B027-2143-49BC-9D65-1DBA5AE9FE5AQ51069588-9E9C4B23-4DCD-4267-8519-24BA94BBD83EQ52587327-E9465AAA-B5BD-4D4D-9666-D404506F65B0
P2860
Suppression of prostate cancer cell rolling and adhesion to endothelium by 1α,25-dihydroxyvitamin D3.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Suppression of prostate cancer ...... by 1α,25-dihydroxyvitamin D3.
@ast
Suppression of prostate cancer ...... by 1α,25-dihydroxyvitamin D3.
@en
Suppression of prostate cancer ...... by 1α,25-dihydroxyvitamin D3.
@nl
type
label
Suppression of prostate cancer ...... by 1α,25-dihydroxyvitamin D3.
@ast
Suppression of prostate cancer ...... by 1α,25-dihydroxyvitamin D3.
@en
Suppression of prostate cancer ...... by 1α,25-dihydroxyvitamin D3.
@nl
prefLabel
Suppression of prostate cancer ...... by 1α,25-dihydroxyvitamin D3.
@ast
Suppression of prostate cancer ...... by 1α,25-dihydroxyvitamin D3.
@en
Suppression of prostate cancer ...... by 1α,25-dihydroxyvitamin D3.
@nl
P2093
P2860
P1476
Suppression of prostate cancer ...... by 1α,25-dihydroxyvitamin D3.
@en
P2093
Deanne Mickelsen
Huei-Ju Ting
Joel C Wojciechowski
Jong-Wei Hsu
Martha L Blair
Michael R King
Sayeda Yasmin-Karim
Wen-Lung Ma
Yi-Fen Lee
P2860
P304
P356
10.1016/J.AJPATH.2010.10.036
P407
P577
2011-02-01T00:00:00Z